ACM
CERE

Aquatic Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Aquatic Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,200
Closed -$257K – 1853
2022
Q4 		$257K Buy
+8,200
New +$231K 0.02% 683

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Aquatic Capital Management's CERE Position: Q1 2023 in Review

Aquatic Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2023, closing a stake of 8,200 shares — an estimated $257K sold.

Aquatic Capital Management first reported a position in CERE in Q4 2022 and held it in 1 quarter. The position peaked at $257K in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q1 2023.

  • Aquatic Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 8,200 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2023, an estimated $257K.
  • Aquatic Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Aquatic Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $257K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2023.

Based on Aquatic Capital Management's 13F filing for Q1 2023, filed 15 May 2023.